Amid the share pricing bust and short lived booms, there is hope for some companies with strong balance sheets. The continual issue is without capital market access, most if not all will wither on the vine as operating costs soar

Friday’s movers and shakers trading forecast; Subscription required:



Fact finding, checking and "gut churn"

Closing Bell


There’s nothing really new and surprising in the stem, cell and gene therapy RegMed sector. Sentiment is in the dumpster and share pricing has more downside risk and obstacles to overcome – the companies themselves!

Subscription required:

Clear and Present Dangers

“Clear and Present Dangers” have become a public metaphor with various applications; mine involves the levels of executive compensation, salary, bonus, options, grants, payments for board participation and other bennies or reimbursed factors  that investors have a RIGHT to … KNOW! 

Read more